RxDoctor Payments Data

Thomas Fields, PA

Physician Assistant · Bastrop, TXNPI 1346443900

Payments from drug & device makers

$1,713in general payments, 2019–2025

Across 92 payments — averaging $18.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$225
  • Lilly USA, LLC$171
  • GSK$157
  • Pfizer$138
  • Genentech USA, Inc.$107
  • Boehringer Ingelheim$89
  • plus $826 from 27 others

What the payments were for

  • Food & beverage$1,65296%
  • Other$614%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,713 in reported general payments places this provider in the 70th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$84,055
Medicare patients
309
Services billed
2,585

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide70$105,455
JanuviaSitagliptin Phosphate54$63,775
MounjaroTirzepatide38$49,666
XareltoRivaroxaban19$27,189
TrulicityDulaglutide17$24,544
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$22,563
JardianceEmpagliflozin18$20,654
EliquisApixaban19$20,323
MyrbetriqMirabegron20$19,582
Nurtec OdtRimegepant Sulfate12$11,149
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog12$10,687
Icosapent Ethyl22$7,480
VascepaIcosapent Ethyl14$5,853
Rosuvastatin Calcium378$3,962
Levothyroxine Sodium327$3,509

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$225$105,45570 claims
Lilly USA, LLCMounjaro, Trulicity$171$74,21055 claims
PfizerEliquis, Nurtec Odt$138$31,47331 claims
Johnson & JohnsonXarelto$17$27,18919 claims
GSKTrelegy Ellipta$157$22,56321 claims
Boehringer IngelheimJardiance$89$20,65418 claims
Astellas Pharma US IncMyrbetriq$18$19,58220 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$13$3,509327 claims
AbbVieSynthroid$61$98123 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Bastrop

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →